Japan’s cost-effectiveness assessment (CEA) panel has approved a revised handling policy for the CEA system for FY2026, with the health…
HOME > ARCHIVE
ARCHIVE
- Korosho to Select 5 Hub Med. Institutions for Early-stage Clinical Studies
July 4, 2011
- Tsuruha HD: Dispensing Fees Up 10.2% in FY2010
July 4, 2011
- EMA to Issue Conclusion on Bladder Cancer Risk from Actos in July
July 4, 2011
- AnGes MG Obtains Patent on HVJ-E for Cancer
July 4, 2011
- R&I Upgrades Kaken's Rating from “Stable”to “Positive”
July 4, 2011
- Takeda Applies for SGN-35 in Europe
July 4, 2011
- Current Users to Be Permitted to Rely on Telemarketing to Buy Reclassified Class 2 OTC Drugs
July 4, 2011
- R&I Keeps AA- Rating for Eisai
July 4, 2011
- Merck Serono Stops Global Approval Process for Cladribine
July 4, 2011
- 3 Groups Reconfirm Opposition to Deregulating Online Sale of OTC Drugs
July 4, 2011
- Mebiopharm to Be Listed on TOKYO AIM on July 15
July 4, 2011
- Largest No. of New Drugs Listed in FY2010 in the Past 15 Years: FPMAJ
July 4, 2011
- JPA Presents Its Opinions on OTC Drug Risk Reclassification to Korosho
July 4, 2011
- Combined Sales of 23 Japanese Drug Companies Reach ¥100 billion in China
July 4, 2011
- FDA Issues Warning on Bladder Cancer Risk Associated with Actos
June 27, 2011
- Pfizer to Conduct First-ever “Virtual Clinical Trial”
June 27, 2011
- Do Practice and Experience Maketh the Marketer?
June 27, 2011
- Korosho to Promptly Assess Bladder Cancer Risk due to Actos
June 27, 2011
- Dacogen Increases OS in AML Patients: Eisai
June 27, 2011
- Aratani Family Excluded from Teva-Controlled Taiyo
June 27, 2011
ページ
The launch of Elevidys has opened the door to gene therapy for DMD, but research into new treatments is already…
I recently sat down with one of the leading medical directors in Japan to discuss the critical evolution of the medical science liaison (MSL) role.The MSL has transformed from a scientific resource into a strategic partner essential for successful product…
Japan’s Central Social Insurance Medical Council (Chuikyo) on November 5 approved the reimbursement listing for a slate of new medicines,…
The Japanese government on March 7 announced new NHI prices to be applied in the FY2025 drug price revision, revealing…
The Japanese government approved a bill to amend the Pharmaceuticals and Medical Devices (PMD) Act at its Cabinet meeting on…
Japan’s health ministry doled out regulatory approvals for a throng of new medicines on December 27 including Eli Lilly’s obesity…
Japan’s all-important reimbursement policy panel on December 20 approved an outline of drug pricing reforms for FY2024, which enshrines a…